核心概念
Hagop Kantarjian honored for transformative leukemia research.
要約
Hagop Kantarjian, MD, receives the 2023 David A. Karnofsky Memorial Award from ASCO for his groundbreaking work in leukemia research. The award recognizes his significant contributions to improving treatment outcomes for various leukemia subtypes. Kantarjian's career achievements span over four decades and have led to the development of innovative therapies that have revolutionized the field of leukemia treatment. His dedication to impactful cancer research and patient care is evident through his extensive body of work and commitment to mentoring the next generation of oncologists.
Highlights:
- Kantarjian's research has dramatically improved survival rates in leukemia patients.
- He has developed several standard-of-care therapies for leukemia subtypes.
- Kantarjian's advocacy for affordable drug therapies highlights the importance of universal healthcare access.
- The award recognizes his lifelong commitment to impactful cancer research and patient care.
統計
"Kantarjian has authored more than 2200 peer-reviewed articles and more than 100 book chapters."
"The David A. Karnofsky Memorial Award includes a $25,000 honorarium."
"Kantarjian hopes new legislation will eventually turn the tide on high cancer drug costs."
引用
"Four decades ago, most of the leukemias were incurable. Today, most of the leukemias are potentially curable with targeted therapies. That's what I am most proud of." - Hagop Kantarjian
"Drug costs have been increasing over time. If you think about it, even if you discover a drug that cures cancer, but the drug is affordable for the 1% of the patients, then you have no cure for cancer." - Hagop Kantarjian